Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)
Roy S. Herbst, MD, PhD, FACP, FASCO
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
